Compare TMC & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMC | NEO |
|---|---|---|
| Founded | 2011 | 2001 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Precision Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 2020 | 2008 |
| Metric | TMC | NEO |
|---|---|---|
| Price | $2.45 | $16.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 12 |
| Target Price | $10.90 | ★ $21.85 |
| AVG Volume (30 Days) | ★ 4.5M | 2.0M |
| Earning Date | 11-12-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 232.00 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.71 |
| Revenue Next Year | N/A | $9.96 |
| P/E Ratio | $13.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.41 | $7.07 |
| 52 Week High | $10.05 | $20.15 |
| Indicator | TMC | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 23.68 | 44.46 |
| Support Level | N/A | $15.57 |
| Resistance Level | $4.81 | $17.19 |
| Average True Range (ATR) | 0.19 | 0.97 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 4.18 | 23.63 |
TMC The Metals Co Inc is a deep seabed minerals developer focused on the collection, processing and refining of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone (CCZ), approximately 1,500 miles (or 2,400 kilometers) south-west of San Diego, California. The company operates as a single operating and reportable segment, namely exploration of seafloor polymetallic nodules, which includes the development of a metallurgical process to treat such seafloor polymetallic nodules.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.